Transcatheter Arterial Chemoembolization Combined with Sorafenib in Treatment of Intermediate or Advanced Hepatocellular Carcinoma of Chinese: A Meta Analysis_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 GAOFei ,  HANBin , PANGZhi-gang , CHENWen-chao

Department of General Surgery, The Second Affiliated Hospital, Zhengzhou University, Zhengzhou 450014, Henan Province, China;

Corresponding?author：

HANBin, Email: hanbin03@163.com

Keywords：

Transcatheter arterial chemoembolization; Sorafenib; Hepatocellular carcinoma; Meta analysis

DOI：

10.7507/1007-9424.20150250

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with sorafenib and TACE only treating the intermediate or advanced hepatocellular carcinoma (HCC) in Chinese people. Methods The PubMed, Embase, Cochrane Library, CBM, CNKI, VIP, and Wanfang Data for randomized controlled trials (RCT) on TACE combined with sorafenib (TACE combined with sorafenib group) and TACE (TACE alone group) from inception to December 2014 were searched. The literatures and data were screened and extracted. The meta analysis was performed using RevMan 5.1 software. Results Six RCTs involving 498 patients with HCC were included. The results of meta analysis showed that the objective response rate[OR=2.28, 95% CI (1.52-3.42), P < 0.000 1] and the disease control rate[OR=6.62, 95% CI (4.12-10.65), P < 0.000 01] were higher, the 1-year survival rate[OR=3.27, 95% CI (2.06-5.22), P < 0.000 01] and 2-year survival rate[OR=4.55, 95% CI (2.28-9.07), P < 0.000 1] were longer, the safety and tolerability of adverse reactions were better in the TACE combined with sorafenib group as compared with the TACE alone group. Conclusions In Chinese people, compared with TACE alone group, TACE combined with sorafenib group have higher objective response rate, disease control rate, 1-year survival rate, and 2-year survival rate. However, due to the lower quality of included literatures, these conclusions should be treated cautiously.

Citation： GAOFei, HANBin, PANGZhi-gang, CHENWen-chao. Transcatheter Arterial Chemoembolization Combined with Sorafenib in Treatment of Intermediate or Advanced Hepatocellular Carcinoma of Chinese: A Meta Analysis. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2015, 22(8): 962-966. doi: 10.7507/1007-9424.20150250 Copy

1.	楊家進, 吳建兵.原發性肝癌綜合介入治療進展.實用肝臟病雜志, 2015, 18(2):118-119.
2.	戴朝六, 賈昌俊.肝細胞癌規范診治流程評價.中國實用外科雜志, 2014, 34(8):690-695.
3.	中華人民共和國衛生部.原發性肝癌診療規范(2011年版).臨床腫瘤學雜志, 2011, 16(10):929-946.
4.	Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma:the BCLC staging classification. Semin Liver Dis, 1998, 19(3):329-338.
5.	曾憲濤, 包翠萍, 曹世義, 等. Meta分析系列之三:隨機對照試驗的質量評價工具.中國循證心血管醫學雜志, 2012, 4(3):183-185.
6.	Review Manager (RevMan)[Computer program]. Version 5.1. Copen-hagen:The Nordic Cochrane Centre, The Cochrane Collaboration, 2011 5.1. http://tech.cochrane.org/revman.
7.	姜海英, 謝曉東.索拉非尼聯合TACE術治療中晚期肝細胞癌30例臨床觀察.海南醫學, 2010, 21(23):6-9.
8.	郭予武.肝動脈栓塞化療術聯合小分子靶向治療晚期肝癌臨床療效觀察.中國醫學工程, 2012, 20(6):11-13.
9.	陳四明, 王豫山, 謝輝.索拉非尼聯合TACE治療老年原發性肝癌的臨床觀察.中國現代醫學雜志, 2012, 22(25):71-73.
10.	曲捷.分子靶向藥物-索拉非尼對晚期肝癌的療效觀察.長春:吉林大學, 2013.
11.	孫恒, 韓文杰. TACE聯合索拉非尼對不能手術切除肝細胞肝癌的療效分析.胃腸病學和肝病學雜志, 2014, 23(5):486-488.
12.	周仁貴, 周錫建, 李相勇, 等.索拉非尼聯合化療栓塞治療晚期原發性肝癌的療效分析.現代生物醫學進展, 2014, 14(13):2494-2496.
13.	戴朝六, 趙陽.原發性肝癌的綜合治療.中國普外基礎與臨床雜志, 2014, 21(2):133-137.
14.	馬坤, 梁定.中晚期肝癌治療進展.國際腫瘤學雜志, 2012, 39(8):612-615.
15.	Fernández M, Semela D, Bruix J, et al. Angiogenesis in liver disease. J Hepatol, 2009, 50(3):604-620.
16.	Liapi E, Geschwind J. Chemoembolization for primary and metas-tatic liver cancer. Cancer J, 2010, 16(2):156-162.
17.	Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008, 359(4):378-390.
18.	Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phaseⅢrandomised, double-blind, placebo-controlled trial. Lancet Oncol, 2009, 10(1):25-34.
19.	De Lope CR, Tremosini S, Forner A, et al. Management of HCC. J Hepatol, 2012, 56:S75-S87.
20.	弋鵬圣, 張鳴, 徐明清.索拉菲尼治療晚期肝癌的療效與安全性評價.中國普外基礎與臨床雜志, 2014, 21(10):1268-1276.
21.	Cotter TG. Apoptosis and cancer:the genesis of a research field. Nat Rev Cancer, 2009, 9(7):501-507.
22.	陳逢生, 崔彥芝, 羅榮城, 等.索拉非尼聯合順鉑對肝癌HepG2細胞的抑制作用.南方醫科大學學報, 2008, 28(9):1684-1687.
23.	Richly H, Schultheis B, Adamietz IA, et al. Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma:results from a phase I extension trial. Eur J Cancer, 2009, 45(4):579-587.
24.	Abou-Alfa GK, Schwartz L, Ricci S, et al. PhaseⅡstudy of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol, 2006, 24(26):4293-4300.
25.	Zhao Y, Wang WJ, Guan S, et al. Sorafenib combined with transar-terial chemoembolization for the treatment of advanced hepatoce-llular carcinoma:a large-scale multicenter study of 222 patients. Ann Oncol, 2013, 24(7):1786-1792.

1. 楊家進, 吳建兵.原發性肝癌綜合介入治療進展.實用肝臟病雜志, 2015, 18(2):118-119.
2. 戴朝六, 賈昌俊.肝細胞癌規范診治流程評價.中國實用外科雜志, 2014, 34(8):690-695.
3. 中華人民共和國衛生部.原發性肝癌診療規范(2011年版).臨床腫瘤學雜志, 2011, 16(10):929-946.
4. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma:the BCLC staging classification. Semin Liver Dis, 1998, 19(3):329-338.
5. 曾憲濤, 包翠萍, 曹世義, 等. Meta分析系列之三:隨機對照試驗的質量評價工具.中國循證心血管醫學雜志, 2012, 4(3):183-185.
6. Review Manager (RevMan)[Computer program]. Version 5.1. Copen-hagen:The Nordic Cochrane Centre, The Cochrane Collaboration, 2011 5.1. http://tech.cochrane.org/revman.
7. 姜海英, 謝曉東.索拉非尼聯合TACE術治療中晚期肝細胞癌30例臨床觀察.海南醫學, 2010, 21(23):6-9.
8. 郭予武.肝動脈栓塞化療術聯合小分子靶向治療晚期肝癌臨床療效觀察.中國醫學工程, 2012, 20(6):11-13.
9. 陳四明, 王豫山, 謝輝.索拉非尼聯合TACE治療老年原發性肝癌的臨床觀察.中國現代醫學雜志, 2012, 22(25):71-73.
10. 曲捷.分子靶向藥物-索拉非尼對晚期肝癌的療效觀察.長春:吉林大學, 2013.
11. 孫恒, 韓文杰. TACE聯合索拉非尼對不能手術切除肝細胞肝癌的療效分析.胃腸病學和肝病學雜志, 2014, 23(5):486-488.
12. 周仁貴, 周錫建, 李相勇, 等.索拉非尼聯合化療栓塞治療晚期原發性肝癌的療效分析.現代生物醫學進展, 2014, 14(13):2494-2496.
13. 戴朝六, 趙陽.原發性肝癌的綜合治療.中國普外基礎與臨床雜志, 2014, 21(2):133-137.
14. 馬坤, 梁定.中晚期肝癌治療進展.國際腫瘤學雜志, 2012, 39(8):612-615.
15. Fernández M, Semela D, Bruix J, et al. Angiogenesis in liver disease. J Hepatol, 2009, 50(3):604-620.
16. Liapi E, Geschwind J. Chemoembolization for primary and metas-tatic liver cancer. Cancer J, 2010, 16(2):156-162.
17. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008, 359(4):378-390.
18. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phaseⅢrandomised, double-blind, placebo-controlled trial. Lancet Oncol, 2009, 10(1):25-34.
19. De Lope CR, Tremosini S, Forner A, et al. Management of HCC. J Hepatol, 2012, 56:S75-S87.
20. 弋鵬圣, 張鳴, 徐明清.索拉菲尼治療晚期肝癌的療效與安全性評價.中國普外基礎與臨床雜志, 2014, 21(10):1268-1276.
21. Cotter TG. Apoptosis and cancer:the genesis of a research field. Nat Rev Cancer, 2009, 9(7):501-507.
22. 陳逢生, 崔彥芝, 羅榮城, 等.索拉非尼聯合順鉑對肝癌HepG2細胞的抑制作用.南方醫科大學學報, 2008, 28(9):1684-1687.
23. Richly H, Schultheis B, Adamietz IA, et al. Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma:results from a phase I extension trial. Eur J Cancer, 2009, 45(4):579-587.
24. Abou-Alfa GK, Schwartz L, Ricci S, et al. PhaseⅡstudy of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol, 2006, 24(26):4293-4300.
25. Zhao Y, Wang WJ, Guan S, et al. Sorafenib combined with transar-terial chemoembolization for the treatment of advanced hepatoce-llular carcinoma:a large-scale multicenter study of 222 patients. Ann Oncol, 2013, 24(7):1786-1792.

Previous Article
Strategies of Endovascular Repair for Complicated Stanford Type B Aortic Dissection
Next Article
Analysis of Related Risk Factors for Pancreatic Fistula Following Pancreaticoduodenec-tomy

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Transcatheter Arterial Chemoembolization Combined with Sorafenib in Treatment of Intermediate or Advanced Hepatocellular Carcinoma of Chinese: A Meta Analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content